C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 1/30 (2006.01)
Patent
CA 2633718
The present invention relates to antibodies with increased affinities that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The present invention further relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
La présente invention concerne des anticorps à affinités accrues qui se lient de préférence à un épitope d'EphA2 exposé sur des cellules cancéreuses, mais pas sur des cellules non cancéreuses. L'invention concerne en outre des méthodes et des compositions destinées au traitement, à la gestion ou à la prévention du cancer, en particulier du cancer métastatique. L'invention concerne également des compositions pharmaceutiques comprenant un ou plusieurs anticorps anti-EphA2 selon l'invention, seuls ou en combinaison avec un ou plusieurs autres agents utiles pour traiter le cancer.
Dall'acqua William
Damschroder Melissa
Kinch Michael
Wu Herren
Medimmune Llc
Smart & Biggar
LandOfFree
Affinity optimized epha2 agonistic antibodies and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Affinity optimized epha2 agonistic antibodies and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Affinity optimized epha2 agonistic antibodies and methods of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1909764